Scarica l'app Stockscreener
10.59
0.86%
0.09
Pre-mercato:
10.79
0.20
+1.89%
Precedente Chiudi:
$10.50
Aprire:
$10.43
Volume 24 ore:
635.04K
Relative Volume:
0.56
Capitalizzazione di mercato:
$625.62M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-2.8699
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
-9.80%
1M Prestazione:
+43.11%
6M Prestazione:
+16.76%
1 anno Prestazione:
-18.29%
Intervallo 1D:
$10.08
$10.79
Intervallo di 1 settimana:
$10.01
$12.01
Portata 52W:
$5.68
$13.60
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Confronta CGEM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.59 | 620.30M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Why Cullinan Therapeutics Inc. stock could benefit from AI revolution2025 Volatility Report & Weekly Hot Stock Watchlists - Newser
How Cullinan Therapeutics Inc. stock benefits from strong dollarJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%What's Next? - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - Setenews
How Cullinan Therapeutics Inc. stock responds to policy changesEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
FDA grants fast track designation to Cullinan’s AML therapy By Investing.com - Investing.com Australia
Cullinan Oncology stock rises after FDA Fast Track designation for leukemia drug - Investing.com Canada
Cullinan Therapeutics receives FDA fast track designation for CLN-049 - marketscreener.com
CGEM Receives FDA Fast Track for CLN-049 in Leukemia Treatment - GuruFocus
Cullinan Therapeutics' CLN-049 Receives FDA Fast Track Designation for Treatment of Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
FDA grants fast track designation to Cullinan’s AML therapy - Investing.com
Cullinan Therapeutics Receives FDA Fast Track Designation - GlobeNewswire
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 4,000 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6%Should You Sell? - MarketBeat
Cullinan Oncology stock price target raised to $36 at Jones Trading - Investing.com Nigeria
Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug - sahmcapital.com
Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential - TipRanks
Foresite Capital Management VI LLC Lowers Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) - Aktiellt
Cullinan Therapeutics (NASDAQ:CGEM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Investors Purchase High Volume of Call Options on Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Is Cullinan Therapeutics Inc (CGEM) positioned for future growth? - Setenews
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data - Investing.com Canada
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data - BioWorld MedTech
BTIG Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
Cullinan Therapeutics (CGEM) Receives PT Upgrade from BTIG Analy - GuruFocus
Cullinan Therapeutics price target raised to $38 from $32 at BTIG - TipRanks
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Cullinan Management Ends Development of CLN-617 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $26.00 - Defense World
Wall Street Zen Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Hold - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Wedbush Reiterates “Outperform” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics' (CGEM) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Cullinan TherapeuticsCullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617 - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% Following Analyst Upgrade - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Otsuka units file for US approval for zipalertinib - The Pharma Letter
Cullinan Therapeutics (CGEM) Advances with FDA Acceptance for Lu - GuruFocus
Cullinan Therapeutics rises on rolling submission for zipalertinib - MSN
HC Wainwright & Co. Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
HC Wainwright & Co. Raises Price Target for CGEM to $26.00 | CGE - GuruFocus
CGEM Advances NDA for Zipalertinib Targeting EGFR Mutations in N - GuruFocus
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics initiate rolling submission of new drug application to US FDA - MarketScreener
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - marketscreener.com
Can Cullinan Therapeutics Inc. stock beat market expectations this quarterGDP Growth & Safe Capital Growth Plans - newser.com
Heatmap analysis for Cullinan Therapeutics Inc. and competitors2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
Visual analytics tools that track Cullinan Therapeutics Inc. performance2025 Pullback Review & Free Verified High Yield Trade Plans - newser.com
How Cullinan Therapeutics Inc. stock trades during market volatilityJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Is Cullinan Therapeutics Inc. reversing from oversold territoryFed Meeting & Fast Gain Stock Trading Tips - newser.com
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):